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Congress of Neurological Surgeons Systematic
Review and Evidence-Based Guideline on
Neuroablative Procedures for Patients With
Cancer Pain
BACKGROUND: Managing cancer pain once it is refractory to conventional treatment
continues to challenge caregivers committed to serving those who are suffering from a
malignancy. Although neuromodulation has a role in the treatment of cancer pain for
some patients, these therapies may not be suitable for all patients. Therefore, neuroablative procedures, which were once a mainstay in treating intractable cancer pain, are again
on the rise. This guideline serves as a systematic review of the literature of the outcomes
following neuroablative procedures.
OBJECTIVE: To establish clinical practice guidelines for the use of neuroablative procedures to treat patients with cancer pain.
METHODS: A systematic review of neuroablative procedures used to treat patients with
cancer pain from 1980 to April 2019 was performed using the United States National
Library of Medicine PubMed database, EMBASE, and Cochrane CENTRAL. After inclusion
criteria were established, full text articles that met the inclusion criteria were reviewed by
2 members of the task force and the quality of the evidence was graded.
RESULTS: In total, 14 646 relevant abstracts were identified by the literature search, from
which 189 met initial screening criteria. After full text review, 58 of the 189 articles were
included and subdivided into 4 different clinical scenarios. These include unilateral somatic
nociceptive/neuropathic body cancer pain, craniofacial cancer pain, midline subdiaphragmatic visceral cancer pain, and disseminated cancer pain. Class II and III evidence was
available for these 4 clinical scenarios. Level III recommendations were developed for the
use of neuroablative procedures to treat patients with cancer pain.
CONCLUSION: Neuroablative procedures may be an option for treating patients with
refractory cancer pain. Serious adverse events were reported in some studies, but were
relatively uncommon. Improved imaging, refinements in technique and the availability of
new lesioning modalities may minimize the risks of neuroablation even further.
The full guidelines can be accessed at https://www.cns.org/guidelines/browse-guidelinesdetail/guidelines-on-neuroablative-procedures-patients-wi.
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a) For patients with unilateral somatic
nociceptive/neuropathic body cancer pain, is
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cordotomy, dorsal root entry zone lesioning
(DREZ), thalamotomy, mesencephalotomy,
or Rhizotomy most effective for pain control
and reducing risk of potential complications?
b) In patients with unilateral somatic
nociceptive/neuropathic
body
cancer
pain, what are the outcome(s) following

ABBREVIATIONS: AANS, American Association of Neurological Surgeons; CNS, Congress of Neurological
Surgeons; DREZ, dorsal root entry zone; RF, radiofrequency
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Craniofacial Cancer Pain
a) For patients with craniofacial cancer pain, is trigeminal
tractotomy, rhizotomy (cranial nerves) or nucleus
caudalis DREZ most effective for pain control and
reducing risk of potential complications?
b) In patients with craniofacial cancer pain, what are the
outcome(s) following trigeminal tractotomy, rhizotomy
(cranial nerves) and nucleus caudalis DREZ that indicate
efficacy of pain control?
Midline Subdiaphragmatic Visceral Cancer Pain
a) For patients with midline subdiaphragmatic visceral
cancer pain, is myelotomy effective for pain control and
reducing risk of potential complications?
b) In patients with midline subdiaphragmatic visceral cancer
pain, what are the outcome(s) following myelotomy that
indicate efficacy of pain control?
Disseminated Cancer Pain
a) For patients with disseminated cancer pain, is cingulotomy effective for pain control and reducing risk of
potential complications?
b) In patients with disseminated cancer pain, what are the
outcome(s) following cingulotomy that indicate efficacy
of pain control?

RECOMMENDATIONS
Unilateral Somatic Nociceptive/Neuropathic Body
Cancer Pain
Rhizotomy
Rhizotomy, both in its percutaneous radiofrequency
(RF)/chemical and open surgical forms may be used to treat
patients with unilateral body cancer pain and occasionally
bilateral cancer pain, but outcomes such as sensory deficit (as
a result of rhizotomy) and occasionally a motor or autonomic
deficit (depending on the nerve(s) ablated) should be considered.
Strength of Recommendation: Level III
DREZ
There is insufficient data to make recommendations regarding
the efficacy of DREZ for unilateral body cancer pain.
Thalamotomy
Mediodorsal and basal thalamotomy (RF or radiosurical)
may be used to treat patients with unilateral somatic
nociceptive/neuropathic body cancer pain. Potential complications such as transient diplopia, confusion, or delirium should
be considered.
Strength of Recommendation: Level III

2 | VOLUME 0 | NUMBER 0 | 2020

Mesencephalotomy
Mesencephalotomy may be used to treat patients with
unilateral somatic nociceptive/neuropathic body cancer pain,
especially as an alternative to cordotomy when pain involves
dermatomes above C5. Potential complications should be
considered including gaze palsy and 0.5% risk of mortality when
performed bilaterally.
Strength of Recommendation: Level III
Thalamotomy may be used to treat patients with unilateral
somatic nociceptive/neuropathic body cancer pain, and may be
more effective for pain involving the face and upper body.
Strength of Recommendation: Level III
Cordotomy
Percutaneous image guided cordotomy may be used
for the treatment of patients with unilateral somatic
nociceptive/neuropathic body cancer pain with an expected
durability of at least 6 mo. Potential complications, including
temporary paresis, should be considered.
Strength of Recommendation: Level II
Craniofacial Cancer Pain
Cranial nerve rhizotomy may be used for pain control in
patients with craniofacial cancer pain.
Strength of Recommendation: Level III
Nucleus caudalis DREZ may be used for pain control in
patients with craniofacial cancer pain.
Strength of Recommendation: Level III
Trigeminal tractotomy-nucleotomy may be used for pain
control in patients with craniofacial cancer pain.
Strength of Recommendation: Level III
There is insufficient evidence to recommend one procedure
over the other (trigeminal tractotomy, cranial nerve rhizotomy,
or caudalis DREZ) for pain control in patients with craniofacial
cancer pain.
Midline Subdiaphragmatic Visceral Cancer Pain
Myelotomy (open or percutaneous) may be used to treat
patients with midline sub-diaphragmic visceral cancer pain.
Strength of Recommendation: Level III
There is not enough evidence in literature to suggest a size of
the myelotomy lesion or to favor open vs percutaneous method.
Disseminated Cancer Pain
Cingulotomy may be used in patients with diffuse cancer
pain associated with metastatic disease. Risks of postoperative
cognitive and behavioral problems should be considered.
Strength of Recommendation: Level III

INTRODUCTION
Rationale
Cancer-related pain is a significant problem worldwide. Pain
adversely affects functional status as well as quality of life, and
shortens survival in patients with cancer. While the general trend
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cordotomy, DREZ, thalamotomy, mesencephalotomy,
and Rhizotomy that indicate efficacy of pain control?

NEUROABLATIVE PROCEDURES FOR CANCER PAIN PATIENTS

METHODS

• Analyzed clinical outcome data rather than in Vitro analysis
(such as studies of patient samples for molecular markers, biomechanical studies, cadaver studies, etc);
• Was not an in Vitro study (for novel molecular markers, in Vitro
studies were included on patient samples);
• Was not a biomechanical study;
• Was not performed on cadavers;
• Was published in English.
The authors did not include systematic reviews, guidelines, metaanalyses conducted by others, or, manuscripts with unclear underlying pathology of cancer pain. These documents were examined if
their abstract suggested that they might address one of the recommendations, and their bibliographies were searched for additional
studies. Meeting abstracts, editorials, letters, and commentaries were also
excluded.

Writing Group and Question Establishment

Data Collection Process

Members of the Evidence-Based Clinical Practice Guideline
Taskforce, the Joint Section on Pain of the American Association
of Neurological Surgeons (AANS) and the Congress of Neurological
Surgeons (CNS) have prioritized the development of guidelines for
neuroablative procedures for cancer pain. Authors for the development
of guidelines related to neuroablative cancer pain were identified and
screened for conflict of interest. The final author group agreed on a set
of questions addressing the topic and conducted a systematic review
of the literature relevant to neuroablative procedures for cancer pain
treatment.

Abstracts that met the selection criteria mentioned above were
retrieved in full-text form. Each article’s adherence to the selection criteria
was confirmed. To determine how the data should be classified, the information in the full-text articles was evaluated to determine whether they
provided results of therapy or focused on diagnostic/prognostic information. Agreement on these assessments, on the salient points regarding
the type of study design and objectives, conclusions and data classification was reached by exchanging e-mail correspondence. The information was then used for construction of evidence tables.

Literature Search

The quality of evidence was rated using an evidence hierarchy
for therapeutic studies. The hierarchy is shown in Table 3:
Rating Evidence Quality. Additional information regarding
the hierarchy classification of evidence can be located here:
https://www.cns.org/guidelines/guideline-development-methodology.

The task force members collaborated with a medical librarian to search
the US National Library of Medicine PubMed database, EMBASE, and
Cochrane CENTRAL for the period from January 1, 1980, to April
24, 2019, using the search strategies provided in Table 1. The literature
search yielded 14 646 unique results. The task force selected 189 full-text
articles for review. Of these, 131 were rejected for not meeting inclusion
criteria or for being off-topic.

Study Selection and Eligibility Criteria
A total of 189 articles were manually reviewed by the authors with
specific inclusion and exclusion criteria as outlined below. A total of
131 studies did not meet inclusion criteria below and were therefore
excluded. A total of 58 studies were included for definitive analysis.
Two independent reviewers evaluated and abstracted full-text data for
each article, and the 2 sets of data were compared for agreement by a
third reviewer. Articles with inconsistencies between reviewers were rereviewed, and disagreements were resolved by consensus. To be included
in this preparation of the guidelines, an article had to meet the following
criteria:
• Describes ablative neurosurgical procedures for cancer pain
(studies describing other pathology in addition to cancer pain
were not excluded);
• Includes at least 5 adult human patients (≥18 yr of age) treated
for cancer pain;
• Was published in the English language between January 1, 1980
and April 24, 2019;
• Presents quantitative results;

NEUROSURGERY

Rating Quality of Evidence

Revision Plans
In accordance with the Institute of Medicine’s standards for developing clinical practice guidelines, the task force will monitor related
publications following the release of this document and will revise the
entire document and/or specific sections “if new evidence shows that a
recommended intervention causes previously unknown substantial harm;
that a new intervention is significantly superior to a previously recommended intervention from an efficacy or harms perspective; or that a
recommendation can be applied to new populations.”2 In addition, the
task force will confirm within 5 yr from the date of publication that the
content reflects current clinical practice and the available technologies for
neuroablative procedures for cancer pain.

RESULTS
Four clinical scenarios were identified for this guideline
including: unilateral somatic nociceptive/neuropathic body
cancer pain, craniofacial cancer pain, midline subdiaphragmatic
visceral cancer , and disseminated cancer pain. A total of 58
studies met inclusion criteria and were included in this systematic
review. The included studies were graded as Class II or III
evidence.
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in the last few decades of the twentieth century has been a
departure from ablation of the nervous system, central nervous
system ablation for cancer pain has been re-introduced as a
treatment option in select instances, such as cordotomy for
mesothelioma.1
On this basis, this clinical practice guideline for the use
of neurosurgical ablation for cancer pain was developed. This
guideline will be updated as imaging improves, technical expertise
expands, and lesioning modalities continue to evolve. This
guideline is organized into four clinical cancer pain scenarios for
ease of use and applicability in real clinical settings. The search,
however, was approached by procedure, due to the nature of
organization of relevant literature, which is procedure based.

RASLAN ET AL

Rhizotomy
Seven reports of rhizotomy for cancer-related neuropathic pain
were identified (Table 4A),3-9 all of which were case series and,
therefore, determined to provide Class III level of evidence.
DREZ Lesioning
Three Class III case series were identified (Table 4B).10-12
One manuscript addressed only deafferentation cancer pain, and
two included cancer and noncancer pain. Most patients experienced long-term pain relief, but heterogeneous outcome metrics
and times of evaluation precluded adequate conclusions about
effectiveness.
Thalamotomy
Two reports of thalamotomy for cancer-related chronic neuropathic pain were identified (Table 4C),13,14 both of which were
determined to provide Class III evidence.
Mesencephalotomy
Two reports of mesencephalotomy for cancer pain were
identified (Table 4D).15,16 Both of these studies provide Class III
evidence and include 40 and 202 patients respectively.
Cordotomy
Thirty reports of cordotomy for cancer pain were identified
(Table 4E),7,17-45 suggesting that it is the most studied and
commonly performed ablative procedure for cancer pain. Three
studies were prospective,17,18,31 and many included a large
number of patients (over 100 in some cases), or followed all
patients until death.
Craniofacial Cancer Pain
Cranial Nerve Rhizotomy
There is class III evidence to support the use of cranial
nerve rhizotomy for pain control in patients with craniofacial
cancer pain (Table 5A). A single prospective observational study46
reported that fluoroscopy-guided pulsed RF ablation of the
glossopharyngeal nerve could be an effective therapy for patients
with craniofacial cancer pain in the distribution of the glossopharyngeal nerve.
Nucleus Caudalis DREZ
There is class III evidence to support the use of nucleus
caudalis DREZ for pain control in patients with craniofacial
cancer pain (Table 5B). A single retrospective study12 reported
that open nucleus caudalis DREZ could be an effective treatment
for craniofacial cancer pain, including posterior fossa lymphoma,
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lacrimal carcinoma, temporal meningioma, craniopharyngioma,
and orbital fibrosarcoma.
Trigeminal Tractotomy-Nucleotomy
There is class III evidence to support the use of trigeminal
tractotomy-nucleotomy for pain control in patients with craniofacial cancer pain (Table 5C). A single retrospective study47
reported that percutaneous CT-guided trigeminal tractotomynucleotomy could be an effective treatment for craniofacial cancer
pain.
Midline Subdiaphragmatic Visceral Cancer Pain
Myelotomy
Nine class III studies support the use of myelotomy for
immediate effective pain control for patients with midline subdiaphragmic visceral cancer pain (Table 6). 41,48-52,53,54
Disseminated Cancer Pain
Cingulotomy
Among ablative procedures, cingulotomy can be considered
for patients with diffuse cancer pain, given that it targets pain
processing networks rather than specific ascending pathways.
There were 3 studies detailing the results of cingulotomy
(Table 4).42,55,56 All studies were case series and therefore class
III evidence.

DISCUSSION
Surgical neuroablation was introduced around the inception of
neurosurgery as a specialty.57,58 The decline in the use of neuroablation was concurrent with the discovery and increased utilization
of opioids through multiple formulations and routes. Throughout
its history, neuroablation’s popularity has waxed and waned.59
Neuroablation has been reemerging as a treatment option with
increasingly frequent publications. Given the renewed interest in
neural ablation, a thorough review of the literature and development of clinical practice guidelines on this topic is timely and
necessary.

FUTURE RESEARCH
A multicenter randomized placebo-controlled blinded study
is needed and is currently in process. Alternatively, case control
or matched cohort studies could be developed to obtain
Class II evidence. Furthermore, the majority of papers are
prospective series without control groups. Future studies should
include randomized controlled trials to further evaluate the
efficacy of cordotomy and other ablative procedures.
Guidelines are also an opportunity to identify gaps in
evidence and needs for future research. Neurosurgeons specializing in the treatment of cancer pain should also report and/or
include the following in future studies: self-reported morphine
milligram equivalents pre- and postprocedure, NASS patient
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Unilateral Somatic Nociceptive/Neuropathic Body
Cancer Pain
For patients with unilateral somatic nociceptive or neuropathic
pain, several options for procedure exist including cordotomy,
DREZ, thalamotomy, mesencephalotomy, and rhizotomy.

NEUROABLATIVE PROCEDURES FOR CANCER PAIN PATIENTS

CONCLUSION
Review of the data available for 8 neuroablation procedures
demonstrated class II evidence for cordotomy effectiveness on
the short term and therefore it should be considered as a
treatment option in patients with unilateral somatic pain (level II
recommendation). All other procedures except DREZ had class
III evidence supporting these procedures as an option for the
treatment of the particular type of cancer pain each procedure
is effective against (level III recommendations). Currently there
is not sufficient evidence to recommend DREZ as a treatment
option for unilateral cancer pain.
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Disclaimer of Liability
This clinical, systematic, evidence-based clinical practice guideline update was
developed by a multi-disciplinary physician volunteer taskforce and is provided as
an educational tool based on an assessment of the current scientific and clinical
information regarding the management and treatment of pediatric patients with
hydrocephalus. This guidelines update is disseminated with the understanding
that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and
treatment advice from a patient’s physician(s). If medical advice or assistance is
required, the services of a physician should be sought. The proposals contained in
this guideline update may not be suitable for use in all circumstances. The choice
to implement any particular recommendation contained in this guideline update
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